GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Ins & Outs: C-suite rejigs at Regenxbio, Kyverna and Mirador
Kyverna appoints Warner Biddle as CEO, Christi Shaw to board. Regenxbio welcomes Mitchell Chan as CFO. Mirador Therapeutics appoints Gregg Gilbert as CFO.
Novartis' Kisqali gets expanded FDA OK; Mene Pangalos joins Omega Funds
Novartis' Kisqali gets FDA approval for early-stage breast cancer; GSK's vaccines for RSV and shingles co-administered effectively; Novo Nordisk partners with NanoVation for genetic therapies; AstraZeneca's Mene Pangalos joins Omega Funds; Serán Biosciences secures $200M for new facility; Boehringer Ingelheim's nerandomilast shows success in Phase 3 IPF trial.
GSK Launches Brooke Shields' Led Campaign Promoting Shingles Vaccine
GSK's Thrive@50 campaign, featuring Brooke Shields, educates people over 50 on shingles risks, promoting vaccination discussions with healthcare providers. GSK also partners with Flagship Pioneering to develop novel treatments for respiratory diseases.
Erythropoietin Drugs Market Estimated to Reach USD 14.3
The global erythropoietin drugs market is projected to grow at a CAGR of 3.8% from 2024 to 2034, reaching $14.3 billion by 2034. Advances in precision medicine, regulatory reforms for biosimilars, and telemedicine integration are driving market growth. Key players include Amgen, Roche, and Johnson & Johnson. Epoetin Alfa and biosimilars lead the market segments.
IDEAYA Biosciences Appoints Douglas B. Snyder as Senior Vice President, General Counsel
Douglas B. Snyder joins IDEAYA Biosciences as Senior Vice President, General Counsel on Sept. 18, 2024, bringing over 25 years of legal experience from GW Pharmaceuticals, Actelion Pharmaceuticals, Eisai, GSK, and the U.S. FDA.
Internships and placements
GSK offers apprenticeships, internships, and graduate programs in Belgium, India, Poland, UK, and US. Use the job search for local early career openings.
GSK Ends Development of Herpes Vaccine Candidate After Disappointing Trial Results
GSK’s phase 1/2 trial of HSV vaccine candidate, GSK3943104, failed to meet primary efficacy endpoint, leading to discontinuation of further development. The trial will continue for safety monitoring.
Belantamab Mafodotin Plus Vd Earns Breakthrough Therapy Designation in China for R/R Myeloma
CDE of China’s NMPA grants BTD for belantamab mafodotin-blmf plus Vd in relapsed/refractory multiple myeloma, based on DREAMM-7 trial data showing 36.6-month median PFS vs 13.4 months with DVd.
Sanofi, AstraZeneca Get FDA Approval of New Manufacturing Line to Bolster US Supply of Beyfortus
FDA approves Sanofi and AstraZeneca's new filling line for Beyfortus, enabling expanded manufacturing capacity and supply in the U.S. for the 2024/2025 RSV season. Beyfortus, a long-acting antibody, was FDA-approved in July 2023 for infants and children up to 24 months old at severe risk of RSV infection. CDC analysis in March 2024 showed Beyfortus 90% effective at preventing RSV hospitalization.
© Copyright 2024. All Rights Reserved by MedPath